|
|
Drugs for Light Chain Deposition Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 59)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Dexamethasone | approved, investigational, vet_approved | Phase 3, Phase 1, Phase 2 | 2084 | 50-02-2 | 5743 | (3H)-Dexamethasone .delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol .gamma.corten 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone 1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone 1-Dehydro-16α-methyl-9α-fluorohydrocortisone 137098-19-2 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone 16-alpha-Methyl-9-alpha-fluoroprednisolone 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol 16.alpha.-Methyl-9.alpha.-fluoroprednisolone 16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol 16alpha -Methyl-9alpha -fluoroprednisolone 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone 16alpha-Methyl-9alpha-fluoroprednisolone 16α-Methyl-9α-fluoro-1-dehydrocortisol 23495-06-9 31375_FLUKA 46165_FLUKA 46165_RIEDEL 50-02-2 8054-59-9 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione 9-Fluoro-16-methylprednisolone 9-alpha-Fluoro-16-alpha-methylprednisolone 9.alpha.-Fluoro-16.alpha.-methylprednisolone 906422-84-2 9A-FLUORO-16BETA-METHYLPREDNISOLONE 9alpha -Fluoro-16alpha -methylprednisolone 9alpha-Fluoro-16alpha-methylprednisolone 9alpha-fluoro-16alpha-methyl-Prednisolone 9α-Fluoro-16α-methylprednisolone AC-11056 AC1L1L1H AC1Q29DM AI3-50934 Adexone Aeroseb-D Aeroseb-Dex Aeroseb-dex Ak Dex Oph Otic Soln 0.1% Alcon Brand of Dexamethasone Anaflogistico Aphtasolon Aphthasolone Apo-dexamethasone Auxiron Azimycin (veterinary) Azium Azium (Veterinary) Azium (veterinary) BIDD:ER0494 BIDD:PXR0060 BRD-K38775274-001-02-3 BRD-K38775274-001-06-4 BSPBio_000995 Bisu DS Bisu Ds C15643 C22H29FO5 CCRIS 7067 CHEBI:41879 CHEMBL384467 CID5743 CPD-10549 CPD001227192 Calonat Corson Corsone Cortisumman D00292 D003907 D1756_SIGMA D4902_SIGMA D6645_SIGMA D8893_SIGMA D9184_SIGMA DB01234 DEX DEXA DEXONE 0.5 DEXONE 0.75 DEXONE 1.5 DEXONE 4 DXM DXMS Decacort Decacortin Decaderm Decadron Decadron (TN) Decadron Tablets, Elixir Decadron, Dexamethasone Decadron-LA Decadron-La Decagel Decaject Decaject L.A. Decaject-L.A. Decalix Decameth Decasone Decaspray Dectancyl Dekacort Delta1-9alpha-Fluoro-16alpha-methylcortisol Deltafluorene Dergramin Deronil Desadrene Desametasone Desametasone [DCIT] Desametasone [Dcit] Desamethasone Desameton Deseronil Dex-Ide Dex-ide Dexa Dexa Mamallet Dexa mamallet Dexa-Cortidelt Dexa-Cortisyl Dexa-Mamallet Dexa-Scheroson Dexa-Sine Dexa-cortidelt Dexa-cortisyl Dexa-scheroson Dexa-sine Dexacen-4 Dexacidin Dexacort Dexacortal Dexacortin Dexadeltone Dexafarma Dexair Dexalona Dexaltin Dexametasona Dexametasona [INN-Spanish] Dexametasone | Dexameth Dexamethansone Dexamethasone Dexamethasone (JP15/USP/INN) Dexamethasone Acetate Dexamethasone Alcohol Dexamethasone Base Dexamethasone Intensol Dexamethasone Sodium Phosphate Dexamethasone [INN:BAN:JAN] Dexamethasone alcohol Dexamethasone base Dexamethasone intensol Dexamethasone-omega Dexamethasonum Dexamethasonum [INN-Latin] Dexamethazone Dexamonozon Dexapolcort Dexapos Dexaprol Dexason Dexasone Dexasone 0.5mg Dexasone 0.75mg Dexasone 4mg Dexasporin Dexinolon Dexinoral Dexone Dexone 0.5 Dexone 0.75 Dexone 1.5 Dexone 4 Dexonium Dexpak Dextelan Dezone Dinormon Dxms ECR Brand of Dexamethasone EINECS 200-003-9 FT-0080377 Fluormethylprednisolone Fluormone Fluorocort Fortecortin Foy Brand of Dexamethasone Gammacorten HL-dex HMS1792A17 HMS1990A17 HMS2089N13 HSDB 3053 Hexadecadrol Hexadrol Hexadrol Elixir Hexadrol Tablets Hexadrol elixir Hl-Dex Hl-dex I06-1196 ICN Brand of Dexamethasone IontoDex Isopto-Dex Isopto-dex LS-7300 Lokalison F Lokalison f Loverine Luxazone MK 125 MLS001055412 MLS001332507 MLS001332508 Maxidex Maxidex Ont 0.1% Maxidex Sus 0.1% Maxitrol Mediamethasone Merck Brand of Dexamethasone Merz Brand 1 of Dexamethasone Merz Brand 2 of Dexamethasone Methylfluorprednisolone Mexidex Millicorten MolMap_000018 MolPort-003-846-433 Mymethasone NCGC00091019-01 NCGC00091019-02 NCGC00091019-03 NCGC00091019-04 NCGC00091019-05 NCI60_003067 NSC 34521 NSC34521 Naquasone (veterinary) Neomycin and polymyxin b sulfates and dexamethasone Neomycin and polymyxin b sulphates and dexamethasone OTO-104 Ocu-Trol Ocu-trol Oradexon PHL-dexamethasone PMS-dexamethasone Pet Derm III Pet Derm Iii Pet derm III Pet-Derm Iii Pms Dexamethasone Elixir 0.5mg/5ml Policort Posurdex Prednisolon F Prednisolon f Prednisolone F Prednisolone f Prodex S1322_Selleck SAM002548948 SGCUT00126 SK-Dexamethasone SK-dexamethasone SMP1_000092 SMR000857119 SMR001227192 ST50307091 Sandoz dexamethasone Sk-Dexamethasone Spectrum5_002019 Spoloven Sunia Sol D Sunia sol D Superprednol TL8003317 Tobradex Tobramycin and dexamethasone Tresaderm (veterinary) Turbinaire UNII-7S5I7G3JQL Visumetazone WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1 ZINC03875332 alpha -Fluoro-16-alpha -methylcortisol delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol delta1-9alpha-Fluoro-16alpha-methylcortisol dexamethasone nchembio809-comp2 to_000038 |
| | 2 | | Melphalan | approved | Phase 3, Phase 1, Phase 2 | 712 | 148-82-3 | 4053, 460612 | (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid 148-82-3 3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine 3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3025 C.B. 3025 c.b 3223-07-2 4-(Bis(2-chloroethyl)amino)-L-phenylalanine 4-14-00-01689 (Beilstein Handbook Reference) 4-[Bis(2-chloroethyl)amino]-L-phenylalanine 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine AC1LA2OE ALKERAN (TN) AY3360000 Alanine Nitrogen Mustard Alkeran AmbotzHAA1563 At-290 BIDD:GT0044 BRD-K87827419-001-02-8 BRN 2816456 BSPBio_002407 C13H18Cl2N2O2 CB 3025 CB-3025 CCRIS 374 CHEBI:165415 CHEBI:28876 CHEMBL852 CID460612 D00369 DivK1c_000653 EINECS 205-726-3 HMS2090B09 HMS2091B16 HMS502A15 HSDB 3234 IDI1_000653 KBio1_000653 KBio2_000877 KBio2_003445 KBio2_006013 KBio3_001627 KBioGR_001284 KBioSS_000877 L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine L-PAM L-Phenylalanine mustard L-Sarcolysin L-Sarcolysine L-Sarkolysin LS-15868 LS-865 | Levofalan Levofolan Levopholan M2011_SIGMA MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)) MLS001333666 MLS002153368 Melfalan Melfalano Melfalano [INN-Spanish] Melphalan (JP15/USP/INN) Melphalan [USAN:INN:BAN:JAN] Melphalanum Melphalanum [INN-Latin] Mephalan MolPort-003-665-535 NCGC00090757-01 NCGC00090757-02 NCGC00090757-03 NCI-C04853 NINDS_000653 NIOSH/AY3360000 NSC 241286 NSC 8806 NSC-8806 NSC241286 NSC8806 P-Di-(2-chloroethyl)amino-L-phenylalanine P-L-Sarcolysin P-N-Bis(2-chloroethyl)amino-L-phenylalanine Phenylalanine mustard Phenylalanine nitrogen mustard Prestwick_1006 RCRA waste no. U150 Rcra waste number U150 SK-15673 SMP2_000174 SMR000058720 SPBio_000287 SPECTRUM1500382 Sarcolysine Sarkolysin Spectrum2_000074 Spectrum3_000684 Spectrum4_000882 Spectrum5_001601 Spectrum_000397 TL8001065 TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN) TRANSGENIC MODEL EVALUATION (MELPHALAN) UNII-Q41OR9510P melphalan p-Bis(beta-chloroethyl)aminophenylalanine p-Di-(2-chloroethyl)amino-L-phenylalanine p-L-Sarcolysin p-L-sarcolysine p-N,N-bis(2-chloroethyl)amino-L-phenylalanine p-N-Bis(2-chloroethyl)amino-L-phenylalanine p-N-Di(chloroethyl)aminophenylalanine p-N-di(chloroethyl)aminophenylala nine phenylalanine nitrogen mu stard |
| | 3 | | Mechlorethamine | approved | Phase 3, Phase 2 | 377 | 51-75-2 | 4033 | .Beta.,.beta.'-Dichlorodiethyl-N-methylamine 1, 5-Dichloro-3-methyl-3-azapentane hydrochloride 126-85-2 (N-oxide) 2,2'-Dichloro-N-me 2,2'-Dichloro-N-methyldiethylamine 2,2'-Dichlorodiethyl-methylamine 2,2'-dichloro-N-methyldiethylamine 2-Chloro-N-(2-chloroethyl)-N-methylethanamine 302-70-5 (N-oxide, hydrochloride) 51-75-2 55-86-7 (HYDROCHLORIDE) AC1L1H9H Antimit BRN 0605323 BSPBio_001947 Bis(2-chloroethyl)methylamine Bis(beta-chloroethyl) methylamine Bis(beta-chloroethyl)methylamine C07115 C5H11Cl2N CCRIS 447 CHEBI:28925 CHEMBL427 CID4033 Carolysine Caryolysin Caryolysine Chloramine (the nitrogen mustard) Chlorethazine Chlormethine Chlormethine (INN) Chlormethine [INN:BAN] Chlormethinum [INN-Latin] Cloramin Clormetina Clormetina [INN-Spanish] D07671 DB00888 Di(2-chloroethyl)methylamine Dichlor amine Dichloren DivK1c_000759 EINECS 200-120-5 ENT-25294 Embechine Embichin HMS1920J15 HMS2091B04 HMS502F21 HN-2 HN2 HSDB 5083 I14-8708 IBS-L0033631 IDI1_000759 KBio1_000759 KBio2_001369 KBio2_003937 KBio2_006505 KBio3_001447 | KBioGR_001448 KBioSS_001369 LS-7559 MBA Me chloroethamine Mebichloramine Mechlorethamine Mechlorethanamine Mechloroethamine Mecloretamina Mecloretamina [Italian] Methylbis(2-chloroethyl)amine Methylbis(beta-chloroethyl)amine Methyldi(2-chloroethyl)amine Mitoxine (*Hydrochloride*) MolPort-001-785-592 Mustargen Mustine Mustine note Mutagen N,N-Bis(2-chloroethyl)-N-methylamine N,N-Bis(2-chloroethyl)methylamine N,N-Di(chloroethyl)methylamine N-Lost N-Methyl lost N-Methyl-2,2'-dichlorodiethylamine N-Methyl-bis(2-chloroethyl)amine N-Methyl-bis(beta-chloroethyl)amine N-Methyl-bis-chloraethylamin N-Methyl-bis-chloraethylamin [German] N-Methyl-lost N-Methyl-lost [German] N-methyl-bis(2-chloroethyl)amine NCGC00091835-02 NCGC00091835-03 NCGC00091835-04 NCGC00091835-05 NCI60_041682 NINDS_000759 NSC762 Nitol (*Hydrochloride*) Nitrogen mustard Nitrogen mustard (HN-2) Nitrogranulogen SPBio_000496 SPECTRUM1500375 Spectrum2_000448 Spectrum3_000484 Spectrum4_000924 Spectrum5_001702 Spectrum_000889 Stickstofflost (*Hydrochloride*) Stickstofflost (ebewe) T 1024 T-1024 TL 146 UNII-50D9XSG0VR beta,Beta'-dichlorodiethyl-N-methylamine beta,beta'-Dichlorodiethyl-N-methylamine mechlorethamine thyldiethylamine β,β'-dichlorodiethyl-N-methylamine |
| | 4 | | Lenalidomide | approved | Phase 3, Phase 1, Phase 2 | 718 | 191732-72-6 | 216326 | 1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline 191732-72-6 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione 346670-73-3 443912-14-9 AC-914 AC1L50II AKOS005146276 ALBB-015321 Bio-0168 C467567 CC 5013 CC-5013 CC-5013, Revlimid, Lenalidomide CC5013 CDC 501 CDC-501 CDC-5013 CHEMBL848 CID216326 Celgene brand of lenalidomide D04687 | DB00480 EC-000.2340 ENMD-0997 I06-0831 IMID-1 IMID-5013 IMiD3 IMiD3 cpd IMid-1 LS-184040 Lenalidomide Lenalidomide (USAN/INN) Lenalidomide [USAN] MolPort-003-848-370 NCGC00167491-01 NSC747972 Revamid Revimid Revlimid Revlimid (Celgene) Revlimid (TN) S1029_Selleck STK639603 Thalidomide analog CC-5013 UNII-F0P408N6V4 lenalidomide | |
| | 5 | | Bortezomib | approved, investigational | Phase 3, Phase 2, Phase 1 | 794 | 179324-69-7 | 387447, 93860 | 179324-69-7 AC1L8TUW Bortezomib Bortezomib (JAN/USAN/INN) CHEBI:287372 CHEBI:41143 CHEMBL325041 CID387447 D03150 DB07475 DPBA FT-0082488 I14-3268 LDP-341 LDP341 LPD 341 LPD-341 | MLN341 MolPort-003-845-298 N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide NCI60_029010 NSC-681239 NSC681239 PROSCRIPT BORONIC ACID PS-341 Pyz-Phe-boroLeu S1013_Selleck SBB071337 Velcade Velcade (TN) Velcade, MG-341, PS-341, Bortezomib [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid bortezomib |
| | 6 | | Anti-Bacterial Agents | | Phase 3, Phase 2, Phase 1 | 10884 | | | | 7 | | Anti-Infective Agents | | Phase 3, Phase 2, Phase 1 | 21402 | | | | 8 | | Peripheral Nervous System Agents | | Phase 3, Phase 1, Phase 2 | 22776 | | | | 9 | | Immunoglobulins | | Phase 3, Phase 2, Phase 1 | 6045 | | | | 10 | | protease inhibitors | | Phase 3, Phase 1, Phase 2 | 5320 | | | | | 11 | | Immunoglobulin G | | Phase 3, Phase 2 | 265 | | | | 12 | | Angiogenesis Modulating Agents | | Phase 3, Phase 1, Phase 2 | 4072 | | | | 13 | | Immunosuppressive Agents | | Phase 3, Phase 1, Phase 2 | 12770 | | | | 14 | | Alkylating Agents | | Phase 3, Phase 1, Phase 2 | 4694 | | | | 15 | | Antibodies | | Phase 3, Phase 2, Phase 1 | 6045 | | | | 16 | | Angiogenesis Inhibitors | | Phase 3, Phase 1, Phase 2 | 4143 | | | | 17 | | Antibodies, Monoclonal | | Phase 3, Phase 2, Phase 1 | 3795 | | | | 18 | | Autonomic Agents | | Phase 3, Phase 1, Phase 2 | 9774 | | | | 19 | | Hormones, Hormone Substitutes, and Hormone Antagonists | | Phase 3, Phase 1, Phase 2 | 12767 | | | | 20 | | Antineoplastic Agents, Hormonal | | Phase 3, Phase 1, Phase 2 | 5407 | | | | 21 | | Antineoplastic Agents, Alkylating | | Phase 3, Phase 1, Phase 2 | 4474 | | | | 22 | | Antiemetics | | Phase 3, Phase 1, Phase 2 | 3888 | | | | 23 | | Anti-Inflammatory Agents | | Phase 3, Phase 1, Phase 2 | 10355 | | | | 24 | | Dexamethasone 21-phosphate | | Phase 3, Phase 1, Phase 2 | 2084 | | | | 25 | | BB 1101 | | Phase 3, Phase 1, Phase 2 | 2084 | | | | 26 | | Dexamethasone acetate | | Phase 3, Phase 1, Phase 2 | 2084 | 1177-87-3 | | | 27 | | Hormones | | Phase 3, Phase 1, Phase 2 | 13979 | | | | 28 | | HIV Protease Inhibitors | | Phase 3, Phase 1, Phase 2 | 5319 | | | | 29 | | Hormone Antagonists | | Phase 3, Phase 1, Phase 2 | 12778 | | | | 30 | | glucocorticoids | | Phase 3, Phase 1, Phase 2 | 4920 | | | | 31 | | Gastrointestinal Agents | | Phase 3, Phase 1, Phase 2 | 8109 | | | | 32 | | phenylalanine | Nutraceutical | Phase 3, Phase 2 | 158 | | | | 33 | | Doxycycline | approved, investigational, vet_approved | Phase 2 | 237 | 564-25-0 | 54671203 | (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide 10597-92-9 17086-28-1 (mono-hydrate) 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS) 24390-14-5 41411-66-9 (6-epimer, mono-hydrochloride) 5-Hydroxy-alpha-6-deoxytetracycline 5-hydroxy-α-6-deoxytetracycline 564-25-0 6-Deoxyoxytetracycline 6-Deoxytetracycline 6-alpha-Deoxy-5-oxytetracycline 6-alpha-deoxy-5-oxytetracycline 69935-17-7 (mono-hydrochloride, di-hydrate) 6alpha-Deoxy-5-oxytetracycline 6alpha-deoxy-5-oxytetracycline 6α-deoxy-5-oxytetracycline 7164-70-7 7264-10-0 94088-85-4 (calcium salt (1:2)) AB08 (*Fosfatex) AC1NQXW7 AC1NS4CW AC1NUYS8 AC1O8PYM Alti-Doxycycline Anhydrous doxycycline Apo-Doxy Atridox Azudoxat BCBcMAP01_000024 BIDD:GT0146 BMY-28689 BPBio1_000951 BSPBio_000863 BSPBio_001936 BU-3839T C06973 CHEBI:50845 CHEMBL1433 CID5281011 CID5353597 CID5463943 CID6713981 CPD001550033 D07876 DB00254 DMSC (*Fosfatex) DOXCYCLINE ANHYDROUS DOXY DOXYCYCLINE CALCIUM DOXYCYCLINE MONOHYDRATE Deoxymykoin DivK1c_000345 Dossiciclina Dossiciclina [DCIT] Doxcycline anhydrous Doxiciclina Doxiciclina [INN-Spanish] Doxiciclina [Italian] Doxitard Doxivetin Doxy-Caps Doxy-Puren Doxy-Tabs Doxycen Doxychel Doxychel (TN) Doxycin Doxycyclin Doxycycline (200mg/day) or Placebo | Doxycycline (INN) Doxycycline (TN) Doxycycline (anhydrous) Doxycycline (internal use) Doxycycline Hyclate Doxycycline Monohydrate Doxycycline anhydrous Doxycycline hyclate Doxycycline-Chinoin Doxycyclinum Doxycyclinum [INN-Latin] Doxysol Doxytec Doxytetracycline EINECS 209-271-1 GS-3065 (*monohydrate) HMS2090E06 HSDB 3071 Hydramycin IDI1_000345 Investin Jenacyclin KBio1_000345 KBio2_001287 KBio2_003855 KBio2_006423 KBio3_001156 KBioGR_001133 KBioSS_001287 LS-187766 LS-93868 Liviatin Lopac0_000405 MolPort-002-507-423 Monodox Monodox (*monohydrate) NCGC00161602-01 NCGC00161602-03 NCGC00161602-04 NCGC00167961-01 NCGC00179395-01 NINDS_000345 NSC633557 Novo-Doxylin Nu-Doxycycline Oracea Prestwick0_000852 Prestwick1_000852 Prestwick2_000852 Prestwick3_000852 Ronaxan SAM002589932 SMP1_000107 SPBio_000246 SPBio_002784 STOCK1N-34341 Spanor Spectrum2_000143 Spectrum3_000408 Spectrum4_000527 Spectrum5_000947 Spectrum_000807 Supracyclin UNII-334895S862 UPCMLD-DP021 UPCMLD-DP021:001 Vibra-tabs Vibramycin Vibramycin (*monohydrate) Vibramycin Novum Vibramycine Vibravenos Vivox (*Hyclate) alpha-6-Deoxy-5-hydroxytetracycline alpha-6-Deoxyoxytetracycline alpha-Doxycycline doxycycline |
| | 34 | | Bevacizumab | approved, investigational | Phase 2 | 1968 | 216974-75-3 | | 216974-75-3 Avastin Avastin (TN) Bevacizumab Bevacizumab (genetical recombination) | Bevacizumab (genetical recombination) (JAN) D06409 R-435 anti-VEGF monoclonal antibody antiVEGF bevacizumab | |
| | 35 | | Paclitaxel | approved, vet_approved | Phase 2 | 2758 | 33069-62-4 | 36314 | (2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine 157069-30-2 33069-62-4 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv. 7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv. 7-Epi-Paclitaxel 7-Epi-Taxol 7-Epipaclitaxel 7-Epitaxol 7-epi-Paclitaxel 7-epi-Taxol AB00513812 ABI 007 ABI-007 ABI007 AC-675 AC1L1IOG AC1L1VJI AC1L9AVF ACon1_002231 ANX-513 Abraxane Abraxane (TN) Abraxane I.V. Suspension Abraxis BioScience brand of albumin-bound paclitaxel Ambotz33069-62-4 Anzatax Asotax BIDD:PXR0046 BMS 181339-01 BMS-181339 BMS-181339-01 BPBio1_000320 BRD-A23723433-001-01-2 BRD-A28746609-001-04-0 BRD-K62008436-001-03-1 BSPBio_000290 BSPBio_001152 BSPBio_002614 Bio-0076 Bio1_000362 Bio1_000851 Bio1_001340 Bio2_000416 Bio2_000896 Bristaxol C07394 C466458 C47H51NO14 CCRIS 8143 CHEBI:103439 CHEBI:45863 CHEMBL100910 CHEMBL418410 CHEMBL48 CID36314 CID441276 CID4666 CID6713921 CID6915727 CPD-8718 Capxol D00491 DB01229 DHP-107 DHP-208 DRG-0190 DTS-301 DivK1c_000441 EU-0101201 Ebetaxel EmPAC Epitaxol Genaxol Genetaxyl Genexol Genexol-PM HMS1362J13 HMS1568O12 HMS1792J13 HMS1922K08 HMS1990J13 HMS2090D07 HMS2093K15 HMS501G03 HSDB 6839 I06-0014 IDI1_000441 IDI1_002171 Intaxel KBio1_000441 KBio2_000492 KBio2_002016 KBio2_002509 KBio2_003060 KBio2_004584 KBio2_005077 KBio2_005628 KBio2_007152 KBio2_007645 KBio3_000903 KBio3_000904 KBio3_001834 KBio3_002987 KBioGR_000492 KBioGR_001893 | KBioGR_002509 KBioSS_000492 KBioSS_002016 KBioSS_002517 LMPR0104390001 LS-31070 LipoPac Lopac0_001201 MBT 0206 MEGxp0_001940 MLS000863266 MLS001077297 MLS002154218 MLS002172439 MLS002695976 MPI-5018 Micellar Paclitaxel Mitotax MolPort-001-742-627 MolPort-003-665-783 MolPort-003-932-365 NCGC00024995-02 NCGC00024995-03 NCGC00024995-04 NCGC00024995-05 NCGC00024995-06 NCGC00024995-07 NCGC00164367-01 NCGC00164367-02 NCGC00164367-03 NCI60_000601 NINDS_000441 NK 105 NP-010981 NSC 125973 NSC-125973 NSC125973 NSC358882 Nanotaxel Neuro_000060 Nova-12005 OAS-PAC-100 OncoGel Onxal Onxol Onxol, Taxol, Nov-Onxol, Paclitaxel P1632 Paclical Pacligel Paclitaxel Paclitaxel (JAN/USP) Paclitaxel (JAN/USP/INN) Paclitaxel (Taxol) Paclitaxel [USAN:INN:BAN] Paxceed Paxene Paxoral Plaxicel Praxel Prestwick0_000155 Prestwick1_000155 Prestwick2_000155 Prestwick3_000155 Probes2_000350 QW 8184 S-8184 Paclitaxel Injectable Emulsion S1150_Selleck SDCCGMLS-0066823.P001 SDP-013 SMP1_000228 SMR000394086 SMR000857385 SPBio_000943 SPBio_002229 SPECTRUM1503908 ST50306996 Spectrum2_000872 Spectrum3_001057 Spectrum4_001197 Spectrum5_001491 Spectrum_001536 T 7402 T1912_SIGMA T7191_SIGMA T7402_SIGMA TA1 TAXOL (TN) TAXOL, 10-EPI, TXL TaxAlbin Taxol Taxol A Taxol Konzentrat Taxol.RTM. (Registered Trademark) UNII-P88XT4IS4D UPCMLD-DP108:001 UPCMLD-DP108:002 Vascular Wrap Xorane Yewtaxan abi-007 albumin-bound paclitaxel cMAP_000068 nab-paclitaxel nchembio.188-comp1 nchembio.2007.34-comp9 nchembio.215-comp9 nchembio853-comp6 paclitaxel weekly paclitaxel |
| | 36 | | Doxorubicin | approved, investigational | Phase 2 | 1714 | 23214-92-8 | 31703 | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione 111266-55-8 14-Hydroxydaunomycin 14-Hydroxydaunorubicine 14-hydroxydaunomycin 14-hydroxydaunorubicine 23214-92-8 23257-17-2 24385-08-8 25311-50-6 25316-40-9 25316-40-9 (hydrochloride) 29042-30-6 AC1L1M5T AC1Q29OJ ADM ADR Adriablastin Adriacin (hydrochloride salt) Adriamycin Adriamycin PFS Adriamycin PFS (hydrochloride salt) Adriamycin RDF Adriamycin RDF (hydrochloride salt) Adriamycin Semiquinone Adriamycin semiquinone Adriblas tina Adriblastin Adriblastina Adriblastina (TN) Adriblastina (hydrochloride salt) Aerosolized Doxorubicin BPBio1_000502 BRD-K92093830-003-04-3 BSPBio_000456 BSPBio_001031 C01661 C27H29NO11 CCRIS 739 CHEBI:28748 CHEMBL179 CID31703 Caelyx Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74 Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120 D03899 DB00997 DM2 DOX-SL Doxil Doxo Doxorubicin Doxorubicin (USAN/INN) Doxorubicin HCl | Doxorubicin Hydrochloride Doxorubicin [USAN:INN:BAN] Doxorubicin citrate Doxorubicin hydrochloride (hydrochloride salt) Doxorubicin-P4/D10 Doxorubicin-P4/D10 conjugate Doxorubicin-hLL1 Doxorubicin-hLL1 conjugate Doxorubicina Doxorubicina [INN-Spanish] Doxorubicine Doxorubicine [INN-French] Doxorubicinum Doxorubicinum [INN-Latin] EINECS 245-495-6 FI 106 Farmablastina (hydrochloride salt) HMS2089H06 HSDB 3070 Hydroxydaunomycin hydrochlor ide (hydrochloride salt) Hydroxydaunomycin hydrochloride (hydrochloride salt) Hydroxydaunorubicin Hydroxydaunorubicin hydrochloride (hydrochloride salt) JT9100000 LMPK13050001 LS-1029 LS-165655 MLS000759533 Myocet NCI-C01514 NChemBio.2007.10-comp13 NDC 38242-874 NIOSH/JT9100000 NSC 123127 Prestwick0_000438 Prestwick1_000438 Prestwick2_000438 Prestwick3_000438 Probes1_000151 Probes2_000129 RDF Rubex Resmycin Rubex Rubex (hydrochloride salt) SMP1_000106 SPBio_002395 TLC D-99 ThermoDox Triferric doxorubicin UNII-80168379AG adiblastine (hydrochloride salt) adr iablatina (hydrochloride salt) adriablastine (hydrochloride salt) adriablatina (hydrochloride salt) adriblatina (hydrochloride salt) doxorubicin nchembio809-comp5 |
| | 37 | | Carboplatin | approved | Phase 2 | 1980 | 41575-94-4 | 10339178, 498142, 38904 | (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum /h1-3H2,(H,7,8)(H,9,10) /q 1,1-Cyclobutanedicarboxylate diammine platinum (II) 1,1-Cyclobutanedicarboxylate diammine platinum(II) 2*-1 2*1H2 41575-94-4 70903-55-8 AC-1457 AC1L8I6U Ambap41575-94-4 BSPBio_003145 C 2538 C2043 C2538_SIGMA C6H10N2O4Pt CBDCA CCRIS 3404 CHEBI:31355 CHEMBL1351 CHEMBL288376 CID10339178 CID2567 CID38904 CID426756 CID498142 CID5352133 CID6398587 CID6603770 Carbopaltin Carboplatin Carboplatin (JAN/USP/INN) Carboplatin (USAN) Carboplatin [USAN:INN:BAN:JAN] Carboplatine Carboplatine [French] Carboplatino Carboplatino [Spanish] Carboplatinum Carboplatinum [Latin] Cbdca Cyclobutane-1,1-dicarboxylate D01363 DB00958 Diammine(1,1-cyclobutanedicarboxylato)platinum (II) Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum Diammine-1,1-cyclobutane dicarboxylate platinum II DivK1c_000892 EINECS 255-446-0 EU-0100230 Ercar HMS1921J16 HMS2090M05 HMS2092B22 HMS502M14 HSDB 6957 I14-2390 IDI1_000892 IUPAC: Azane InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6 | JM 8 JM-8 KBio1_000892 KBio2_002009 KBio2_004577 KBio2_007145 KBio3_002645 KBioGR_000713 KBioSS_002009 LS-117689 Lopac-C-2538 Lopac0_000230 MolPort-003-665-501 MolPort-003-845-609 NCGC00015223-01 NCGC00093695-01 NCGC00094961-01 NCGC00094961-02 NCGC00094961-03 NCGC00162099-01 NCGC00162099-02 NCGC00167800-01 NCGC00178242-01 NINDS_000892 NSC 201345 NSC 241240 NSC-241240 NSC201345 NSC241240 Paraplatin Paraplatin (TN) Paraplatin, Carboplatin Paraplatin-AQ Platinum(+2) Cation Platinum(II), (1, 1-cyclobutanedicar Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2) Platinum, {diammine[1,1-cyclobut S1215_Selleck SPBio_000716 SPECTRUM1502106 Spectrum2_000898 Spectrum3_001503 Spectrum4_000337 Spectrum5_001094 Spectrum_001529 UNII-BG3F62OND5 azanide carboplatin cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii) cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II) cis-Diammine(1,1-cyclobutanedicarboxylato) platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diammine(cyclobutanedicarboxylato)platinum II cyclobutane-1,1-dicarboxylic acid diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum nchembio.573-comp10 nchembio773-comp2 nchembio873-comp3 platinum(2+) |
| | 38 | | Cyclophosphamide | approved, investigational | Phase 2 | 2829 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Anhydrous cyclophosphamide Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 | DB00531 DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide |
| | 39 | | Cisplatin | approved | Phase 2 | 2690 | 15663-27-1 | 84093, 441203, 2767 | (SP-4-1)-diamminedichloridoplatinum (SP-4-1)-diamminedichloroplatinum (SP-4-2)-diamminedichloridoplatinum (SP-4-2)-diamminedichloroplatinum Abiplatin Biocisplatinum Briplatin CACP CDDP CHEBI:35852 CID441203 CPD0-1392 CPDC CPDD Carboquone Cis Pt II Cis-DDP Cis-Diaminedichloroplatinum Cis-Diamminedichloroplatinum Cismaplat Cisplatine Cisplatino Cisplatinum Cisplatyl Citoplationo DB00515 DDP DDPT Diamminedichloroplatinum | EU-0100918 Lederplatin Neoplatin Peyrone's chloride Peyrone's salt Plastin Platamine Platiblastin Platidiam Platinex Platinol Platinol-AQ Platinoxan Platinum Ammine Chloride Platinum Ammonium Chloride Platinum Diamine Dichloride Randa Trans-DDP Trans-Diaminedichloroplatinum Trans-Diamminedichloroplatinum Trans-Dichlorodiammine Platinum Trans-Platinumdiammine Dichloride cis-DDP cis-Diamminedichloroplatinum cis-Dichlorodiammineplatinum(II) cis-[PtCl2(NH3)2] cis-diamminedichloridoplatinum(II) cis-diamminedichloroplatinum(II) nchembio773-comp1 trans-diamminedichloridoplatinum(II) | |
| | 40 | | Etoposide | approved | Phase 2 | 1232 | 33419-42-0 | 36462 | (-)-Etoposide 121471-01-0 136598-18-0 201594-04-9 33419-42-0 35317-32-9 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside 51854-34-3 76576-58-4 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one AB00438905 AC1L1FN8 AC1L1VT3 AC1L6246 AC1NR4OG AC1O4WGG AC1O7M1N AC1Q47JJ Ambap33419-42-0 BPBio1_000673 BRD-K37798499-001-02-5 BSPBio_000611 Bio1_000489 Bio1_000978 Bio1_001467 C01576 CCRIS 2392 CHEBI:4911 CHEBI:588795 CHEMBL44657 CID11758093 CID284997 CID3310 CID36462 CID5284558 CID6419930 CID6610299 CPD000112002 D00125 DB00773 DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE, Demethyl Epipodophyllotoxin Ethylidine Glucoside Demethyl-epiodophyllotoxin ethylidene glucoside Demethylepipodophyllotoxin-beta-D-ethylideneglucoside E0675 E1383_SIGMA EINECS 251-509-1 EPE EPEG ETOP Epipodophyllotoxin Epipodophyllotoxin VP-16213 Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside) Eposide Eposin | Eposin, Vepesid, VP-16, Toposar, Etoposide Etopol Etopophos Etopophos (phosphate salt) Etoposid Etoposide Etoposide (JP15/USP/INN) Etoposide (VP16) Etoposide [USAN:INN:BAN:JAN] Etoposido Etoposido [INN-Spanish] Etoposidum Etoposidum [INN-Latin] Etosid HMS1569O13 HMS2052N05 HMS2089F14 HSDB 6517 I06-0248 KBioSS_002410 LS-1214 Lastet MLS000049957 MLS001074951 MLS001424283 MLS002153463 MLS002207239 MLS002222184 MolPort-003-983-431 MolPort-004-905-001 MolPort-004-955-161 NCGC00025056-02 NChemBio.2007.10-comp19 NK 171 NSC 141540 NSC-141540 NSC141540 Prestwick0_000396 Prestwick1_000396 Prestwick2_000396 Prestwick3_000396 Prestwick_211 S1225_Selleck SAM001246880 SMR000112002 SPBio_002532 ST056353 Toposar UNII-6PLQ3CP4P3 VP 16 VP 16 (pharmaceutical) VP 16-213 VP 16213 VP-16 VP-16-213 VePESID (TN) VePesid Vepesid Vepesid J Vepeside ZINC03830818 ZINC03938684 Zuyeyidal etoposide nchembio.573-comp8 nchembio873-comp2 trans-Etoposide |
| | 41 | | Lenograstim | approved | Phase 2 | 1202 | 135968-09-1 | | G-CSF (CHO cell derived) Glycosylated recombinant G-CSF Glycosylated recombinant granulocyte colony stimulating factor | Granulocyte colony stimulating factor 3 (CHO cell derived) Granulocyte colony-stimulating factor lenograstim Lenograstim (genetical recombination) Lenograstim rDNA | |
| | 42 | | Doxil | Approved June 1999 | Phase 2 | 1714 | | 31703 | | Evacet LipoDox Pegylated Liposomal Doxorubicin Hydrochloride liposomal doxorubicin |
| | 43 | | Antiparasitic Agents | | Phase 2 | 2127 | | | | 44 | | Antimalarials | | Phase 2 | 1216 | | | | 45 | | Antiprotozoal Agents | | Phase 2 | 1986 | | | | 46 | | Antineoplastic Agents, Phytogenic | | Phase 2 | 5420 | | | | 47 | | Antibiotics, Antitubercular | | Phase 2 | 6972 | | | | 48 | | Topoisomerase Inhibitors | | Phase 2 | 4945 | | | | 49 | | Antimitotic Agents | | Phase 2 | 5498 | | | | 50 | | Antirheumatic Agents | | Phase 2 | 10627 | | |
Interventional clinical trials: (show all 19)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis | Completed | NCT01078454 | Phase 3 | | 2 | Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis | Completed | NCT00344526 | Phase 3 | | 3 | Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma | Recruiting | NCT01169337 | Phase 3 | | 4 | The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis | Recruiting | NCT02312206 | Phase 3 | | 5 | Safety and Effect of Doxycycline in Patients With Amyloidosis | Unknown status | NCT01677286 | Phase 2 | | 6 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | Completed | NCT00621400 | Phase 1, Phase 2 | | 7 | Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis | Completed | NCT00607581 | Phase 2 | | 8 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | Completed | NCT00861705 | Phase 2 | | 9 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | Recruiting | NCT01849783 | Phase 2 | | 10 | Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease | Active, not recruiting | NCT00520767 | Phase 2 | | 11 | HD Melphalan and SCT in Patients With IGDD or LCDD | Terminated | NCT00681044 | Phase 2 | | 12 | Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | NCT01533194 | Phase 1 | | 13 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | Completed | NCT00890747 | Phase 1 | | 14 | Radioimmunoimaging of Light Chain (AL) Amyloidosis | Completed | NCT01815086 | Phase 1 | | 15 | First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD | Recruiting | NCT01728259 | Phase 1 | | 16 | Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis | Recruiting | NCT02338427 | | | 17 | Molecular Imaging of Primary Amyloid Cardiomyopathy | Recruiting | NCT02641145 | | | 18 | Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects | Active, not recruiting | NCT01018927 | | | 19 | Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | Active, not recruiting | NCT01383759 | |
|
